5304-21-2

Basic information

• Product Name: 6-BROMO-2-METHYL-1,3-BENZOTHIAZOLE
• Synonyms: 6-BROMO-2-METHYL-1,3-BENZOTHIAZOLE;6-BROMO-2-METHYLBENZOTHIAZOLE;Benzothiazole, 6-bromo-2-methyl-;6-broMo-2-Methylbenzo[d]thiazole
• CAS NO: 5304-21-2
• Molecular Formula: C₈H₆BrNS
• Molecular Weight: 228.10894
• Mol File: 5304-21-2.mol

Chemical Properties

• Melting Point: 82-84
• Boiling Point: 299.1 °C at 760 mmHg
• Flash Point: 134.7 °C
• Appearance: /
• Density: 1.644 g/cm³
• Vapor Pressure: 0.00217mmHg at 25°C
• Refractive Index: 1.691
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 1.00±0.10(Predicted)
• CAS DataBase Reference: 6-BROMO-2-METHYL-1,3-BENZOTHIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-2-METHYL-1,3-BENZOTHIAZOLE(5304-21-2)
• EPA Substance Registry System: 6-BROMO-2-METHYL-1,3-BENZOTHIAZOLE(5304-21-2)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 5304-21-2(Hazardous Substances Data)

Usage

Chemical Properties

Pale yellow liquid

InChI:InChI=1/C8H6BrNS/c1-5-10-7-3-2-6(9)4-8(7)11-5/h2-4H,1H3

Upstream product

• 2941-62-0 6-amino-2-methylbenzothiazole 
• 5304-17-6 (6-bromo-benzothiazol-2-yl)-malonic acid diethyl ester 
• 120-75-2 2-Methylbenzothiazole 
• 7726-95-6 bromine 
• 64-19-7 acetic acid 
• 20980-00-1 N-(4-bromophenyl)thioacetamide 
• 562080-91-5 N-(4-bromo-2-iodophenyl)acetamide 
• 75-07-0 acetaldehyde 
• 137-07-5 2-amino-benzenethiol 
• 15864-32-1 2-amino-6-bromobenzothiazole 
• 475089-07-7 4-bromo-2-(methylthio)aniline 
• 103-88-8 4-bromoacetanilide 
• 607-93-2 2,4,6-tribromoacetanilide 
• 3460-23-9 N-(4-bromo-2-chlorophenyl)acetamide 

Downstream Products

• 101350-55-4 acetic acid-[4-(2-methyl-benzothiazol-6-ylmercapto)-anilide] 
• 105975-21-1 2-methyl-6-(4-nitro-benzenesulfonyl)-benzothiazole 
• 100621-04-3 4-(2-methyl-benzothiazol-6-ylmercapto)-aniline 
• 876500-78-6 C₁₄H₁₁NS₂ 
• 23451-95-8 2-amino-5-bromobenzenethiol 

Relevant articles and documents

Recyclable copper-catalyzed cyclization of o-haloanilides and metal sulfides: An efficient and practical access to substituted benzothiazoles

An efficient heterogeneous copper-catalyzed cyclization of o-haloanilides and metal sulfides has been achieved via the C–S coupling in DMF at 80 or 140 °C in the existence of an MCM-41-bound NHC-Cu(I) catalyst and then intramolecular condensation, delivering a wide range of substituted benzothiazoles in mostly good to high yields. This new MCM-41-NHC-CuI complex can facilely be obtained by a two-step procedure starting from easily accessible and inexpensive reagents and reused more than seven times without any significant loss of its catalytic efficiency. The present protocol has been successfully applied to the gram-scale synthesis of two antitumor agents 5F203 and PMX 610.

Di- tert-butyl Peroxide-Mediated Radical C(sp2/sp3)-S Bond Cleavage and Group-Transfer Cyclization

A novel strategy of cascade radical C(sp2/sp3)-S bond cleavage and group-transfer cyclization is disclosed. Triggered by alkyl radicals, varieties of 2-isocyanoaryl thioethers containing aliphatic, aryl, and heteroaromatic groups can be cleaved and precisely reinstalled to give benzothiazole derivatives. Mechanistic studies reveal that the cascade reaction undertakes an intermolecular pathway, and the inner radical sources (R radicals) exhibit high priority over those of methyl radical origin from di-tert-butyl peroxide.

IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK

The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

RADIOACTIVE IODINE LABELED STYRYL SUBSTITUTED AROMATIC HETEROCYCLIC COMPOUND

PROBLEM TO BE SOLVED: To provide a novel tau protein imaging agent that allows imaging of biological tau protein by a noninvasive, nuclear medical method. SOLUTION: The present invention provides a radioactive iodine labeled styryl substituted aromatic heterocyclic compound represented by a predetermined general formula or a salt thereof, or a radioactive medicine comprising the same. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

Structure-Activity Relationship Study of Heterocyclic Phenylethenyl and Pyridinylethenyl Derivatives as Tau-Imaging Agents That Selectively Detect Neurofibrillary Tangles in Alzheimers Disease Brains

In order to explore novel tau-imaging agents that can selectively detect neurofibrillary tangles in Alzheimers disease (AD) brains, we designed and synthesized a series of heterocyclic phenylethenyl and (3-pyridinyl)ethenyl derivatives with or without a dimethyl amino group. In in vitro autoradiography using AD brain sections, all radioiodinated ligands with a dimethyl amino group bound to Aβ deposits in the sections. In contrast, the ligands without a dimethyl amino group showed different patterns of radioactivity accumulation in the sections depending on the kind of heterocycle contained in their molecules. Particularly, a phenylethenyl benzimidazole derivative ([125I]64) showed marked radioactivity accumulation in the temporal lobe which corresponded with the distribution of tau deposits. [125I]64 also showed the most favorable pharmacokinetics in normal mouse brains (3.69 and 0.06% ID/g at 2 and 60 min postinjection, respectively) among all ligands in this study. Taken together, these results suggest that [123I]64 may be a new candidate tau-imaging agent.

Radioactive iodine labeled compound, and, radioactive pharmaceutical containing the same (by machine translation)

PROBLEM TO BE SOLVED: and compatibility and affinity for both amyloidosis acryloyldimethyltauric, labeled compd. radioactive iodine. SOLUTION: the present invention, N, N-labeled compd. dimethyl benzene amine including radioactive iodine or its salt. Selected drawing: no (by machine translation)

ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON VASCULAR ENDOTHELIAL LIPASE

Disclosed is a compound which is useful as an endothelial lipase inhibitor. A pharmaceutical composition having inhibitory activity on endothelial lipase comprising a compound represented by the formula: , its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is nitrogen-containing hetero ring, Ring A may be substituted with a substituent other than a group represented by the formula: -C(R1R2)-C(=O)-NR3R4 and a group represented by the formula: -R5, a broken line represents the presence or the absence of a bond, Z is -NR6-, =N-, -O-, or -S-, R6 is halogen, substituted or unsubstituted alkyl or the like, R1 and R2 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy or substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is hydrogen, substituted or unsubstituted alkyl or the like, R3 and R4 taken together with the adjacent nitrogen atom to which they are attached may form a substituted or unsubstituted ring, R5 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or the like.

Regioselective one-pot synthesis of 2-aryl-6-bromobenzothiazole from arylaldehyde and 2-aminothiophenol with phenyltrimethylammonium tribromide in the presence of a catalytic amount of antimony(III) bromide

Various 2-aryl-6-bromo-1,3-benzothiazoles were regioselectively afforded in good yields by the reaction of arylaldehydes and 2-aminothiophenol with phenyltrimethylammonium tribromide in the presence of a catalytic amount of SbBr3 in CH2Cl2 at room temperature.

Thienopyridine and furopyridine kinase inhibitors

Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.